SynBiotic SE (SBX) Fair Value & Analysis
Healthcare · DE · Market cap €13.6M
Fair value as of: Jun 25, 2026
Analysis
SynBiotic SE (SBX) currently trades at €1.11, while our model-based Fair Value estimate is €2.00 — implying the stock looks roughly 79.9% undervalued today. We read business quality at 86/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is SynBiotic SE (SBX) undervalued?
What is the fair value of SBX?
What is the quality score of SBX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.